New CDC Guidelines: People at Risk Should Consider PrEP
May 14, 2014
Health care providers should advise people at "substantial risk" about pre-exposure prophylaxis, or PrEP, to prevent HIV infection, according to new guidelines issued today by the Centers for Disease Control and Prevention (CDC). The FDA approved Truvada (tenofovir/emtricitabine) for PrEP in July 2012.
"HIV infection is preventable, yet every year we see some 50,000 new HIV infections in the United States," said CDC Director Tom Frieden. "PrEP, used along with other prevention strategies, has the potential to help at-risk individuals protect themselves and reduce new HIV infections in the United States."
The guidelines, available online, say PrEP should be considered for the following HIV-negative people:
This excerpt was cross-posted with the permission of BETAblog.org. Read the full article.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)